PT  - JOURNAL ARTICLE
AU  - Ahmed, Sharia M.
AU  - LaPrete, Cormac R.
AU  - Ciglenecki, Iza
AU  - Azman, Andrew S.
AU  - Leung, Daniel T.
AU  - Keegan, Lindsay T.
TI  - Quantifying the population-level impact of expanded antibiotic treatment for cholera outbreak management
AID  - 10.1101/2024.11.04.24316579
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.04.24316579
4099  - http://medrxiv.org/content/early/2024/11/05/2024.11.04.24316579.short
4100  - http://medrxiv.org/content/early/2024/11/05/2024.11.04.24316579.full
AB  - Background Since 2021, there has been a resurgence in the number of cholera cases, countries affected, and the case fatality risk. Partly due to concerns about antibiotic resistance, current cholera treatment guidelines reserve antibiotics for severely symptomatic cases, recommending only supportive care (e.g., oral rehydration) for non-severe cases. However, it has been suggested that the reduction in transmissibility from antibiotic treatment may result in circumstances under which treating mild or moderate cases with antibiotics may have population-level benefits. We developed a compartmental model of cholera transmission in a non-endemic setting to quantify the potential impact of expanded antibiotic treatment on disease burden and antibiotic use. Through simulations, we evaluated different outbreak scenarios, by varying the reproductive number, care-seeking behavior, and proportion of non-severe cases receiving antibiotics. We found that expanding antibiotic treatment could significantly reduce the final outbreak size under certain outbreak characteristics. Under these different transmission scenarios, treating non-severe symptomatic infections with antibiotics decreased cholera transmission and, in some cases, the total number of antibiotic doses used. In high transmission settings, the benefits of expanded treatment are less pronounced and the strategy may lead to increased antibiotic use, potentially increasing the risk of antibiotic resistance. We show that the effectiveness of expanded antibiotic treatment is highly dependent on achieving high care-seeking rates among non-severely symptomatic infections and tailoring the approach to specific outbreak conditions. While expanding antibiotic eligibility could enhance outbreak control in some settings, careful consideration of antibiotic resistance risks is necessary in high-transmission contexts.Competing Interest StatementSMA, LTK acknowledge funding from the CDC Centers for Forecasting and Outbreak Analytics (CFA) (Grant #1NU38FT000009-01-00). CRL, LTK acknowledge funding from the Centers for Disease Control and Prevention (CDC) TRANSMIT: Training Research Acumen in Students Modeling Infectious Threats (Grant #1U01CK000675). ASA acknowledges funding from the National Institutes of Health (Grant #1R01AI179917-01A1) and funding from the Bill and Melinda Gates Foundation (Grant # INV-044856).Funding StatementSMA, LTK acknowledge funding from the CDC Centers for Forecasting and Outbreak Analytics (CFA) (Grant #1NU38FT000009-01-00). CRL, LTK acknowledge funding from the Centers for Disease Control and Prevention (CDC) TRANSMIT: Training Research Acumen in Students Modeling Infectious Threats (Grant #1U01CK000675). ASA acknowledges funding from the National Institutes of Health (Grant #1R01AI179917-01A1) and funding from the Bill and Melinda Gates Foundation (Grant # INV-044856).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis manuscript only uses publicly available data.